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Tinnitus, the phantom perception of sound, is a prevalent disorder. One in 10 adults
has clinically significant subjective tinnitus, and for one in 100, tinnitus severely affects
their quality of life. Despite the significant unmet clinical need for a safe and effective
drug targeting tinnitus relief, there is currently not a single Food and Drug Administration
(FDA)-approved drug on the market. The search for drugs that target tinnitus is hampered
by the lack of a deep knowledge of the underlying neural substrates of this pathology.
Recent studies are increasingly demonstrating that, as described for other central nervous
system (CNS) disorders, tinnitus is a pathology of brain networks. The application of graph
theoretical analysis to brain networks has recently provided new information concerning
their topology, their robustness and their vulnerability to attacks. Moreover, the philosophy
behind drug design and pharmacotherapy in CNS pathologies is changing from that of
“magic bullets” that target individual chemoreceptors or “disease-causing genes” into
that of “magic shotguns,” “promiscuous” or “dirty drugs” that target “disease-causing
networks,” also known as network pharmacology. In the present work we provide
some insight into how this knowledge could be applied to tinnitus pathophysiology and
pharmacotherapy.
Keywords: graph analysis, brain networks, network pharmacology, phantom percept, tinnitus, small-world,
scale-free, magic bullets
TINNITUS PHARMACOTHERAPY: WHERE DO WE STAND?
Tinnitus, the phantom perception of sound, represents a highly
prevalent and distressing condition. Although most cases of tin-
nitus derive from deprivation of auditory input, it goes beyond
the classical definition of an otologic illness, since it encompasses
a range of symptoms that are likely to place a huge burden on
patients and significantly impair quality of life (Jastreboff, 1990).
This can include irritability, agitation, stress, insomnia, anxiety,
and depression. In fact, for one in 100 adults, tinnitus affects their
ability to lead a normal day-to-day life (Vio and Holme, 2005).
Estimates indicate that 13 million people in Western Europe and
the USA currently seek medical advice for their tinnitus (Vio and
Holme, 2005).
The quest toward finding a drug that targets tinnitus has
not been that fulfilling. Although a wide variety of compounds
is used off-label to treat tinnitus patients, there is still no US
Food and Drug Administration (FDA) or European Medicines
Agency (EMA) approved drug on the market. The list of
used compounds includes anticonvulsants, anxiolytic, antide-
pressants, NMDA antagonists, cholinergic antagonists, antihis-
tamines, vasodilators, antipsychotics, and calcium antagonists,
to name a few (Langguth et al., 2009; Elgoyhen and Langguth,
2010). In some cases, the rationale behind the use of them is
to treat the co-morbidities that come along with tinnitus, like
depression and anxiety (Johnson et al., 1993; Sullivan et al., 1993;
Bahmad et al., 2006). In others, it is derived from the use of
drugs which are effective in disorders thought to share some com-
monalities with tinnitus, like anticonvulsants used in epilepsy
(Hoekstra et al., 2011) and the calcium antagonist gabapentin
used in neuropathic pain (Bauer and Brozoski, 2007). Even fur-
ther, some drugs are used based on known underlying neuronal
changes thought to be a neural correlate of tinnitus. Such is the
case of NMDA receptor antagonists (Azevedo and Figueiredo,
2007; Figueiredo et al., 2008; Suckfull et al., 2011) and GABAA
agonists (Johnson et al., 1993; Gananca et al., 2002; Azevedo and
Figueiredo, 2007), used with the hope of reversing the increased
neuronal excitability observed in several regions of the auditory
pathway (Eggermont and Roberts, 2004). Some drugs have been
reported to provide moderate relief of symptoms in a subset of
patients. However, most drugs have not proven sufficient effec-
tiveness in randomized controlled clinical trials in order to be
approved and marketed specifically for tinnitus (Langguth et al.,
2009; Elgoyhen and Langguth, 2010; Langguth and Elgoyhen,
2011).
Thus, novel pharmacological approaches for treating tinni-
tus are required in order to address a widely recognized, yet
largely underserved, and unmet, clinical need. Although early
on classified as an auditory problem, recent work is indicat-
ing that tinnitus is a central nervous system (CNS) disorder,
where dynamic multiple parallel overlapping brain networks are
involved (Eggermont and Roberts, 2004; Schlee et al., 2009a,b; De
Ridder et al., 2011a). Thus, strategies followed in the development
of drugs for other CNS pathologies might give some insight into
possible avenues in the design of tinnitus pharmacotherapies. In
the present work we review some recent trends in the discovery of
CNS acting drugs, describe new ways of analyzing brain networks
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in health and disease and propose how this knowledge could be
extrapolated to tinnitus.
DRUG DISCOVERY IN CNS DISORDERS
Serendipity has played a major role in the initial discovery of CNS
acting compounds, like the first psychotropic drugs that led to
modern pharmacological treatment of psychiatric diseases (Ban,
2006). Although a detailed understanding of the pathophysiology
and etiology of CNS disorders remains elusive, the last decade has
witnessed a huge leap in our understanding of the basic biological
processes that contribute to many humandisorders. However, this
has not been paralled by an increase in the number of approved
new molecular entities. From 1950 to 2008, the FDA approved
1222 new drugs including biologicals (Munos, 2009). Although
the investment of pharmaceutical industries in research and
development has grown from US$2 to $50 billion/year from 1980
to 2005 (Conn and Roth, 2008; Paul et al., 2010), the number of
approved drugs per year, about 25, is not greater than 50 years ago.
Moreover, of those 25, only two were for psychiatric diseases in
2009 (Hughes, 2010). Thus, the scale of investment has not been
matched by output. In addition, there has not been much innova-
tion (Rask-Andersen et al., 2011). For example, the most widely
prescribed antipsychotics olanzapine, risperidone, and quetiap-
ine, share mechanisms of action with clozapine, discovered in
the 1950s (Conn and Roth, 2008). Clozapine was developed as
a chlorpromazine analog, whose antipsychotic actions were dis-
covered serendipitously when being used as a preanesthetic agent
in psychiatric patients (Delay et al., 1952). For more modern
antipsychotics (with the exceptions of aripiprazole and the substi-
tuted benzamides) a major goal has been to create clozapine-like
compounds, devoid of its more serious side effects (Roth et al.,
2004; Conn and Roth, 2008). A similar scenario can be seen in
the case of drugs used for anxiety, depression, and epilepsy. Thus,
the gold standard of drug discovery as from the 1960s has been
the design of more selective drugs with ideally one specific target,
with the aim of reducing side effects (Roth et al., 2004; Hopkins,
2007, 2008; Conn andRoth, 2008). However, over the past decade,
there has been a significant decrease in the rate by which new
drug candidates translated into effective clinical therapies. Even
more striking, there has been a worrying rise in late-stage phase
2 and phase 3 attrition, that is leading to a reduction in revenues
and a financial shock to the pharmaceutical industry (Kola and
Landis, 2004; Hopkins, 2007, 2008). This might derive from the
innermost strategy behind modern drug design: drugs selective
for a single molecular target, the “one gene, one drug, one disease”
paradigm best known as the Paul Ehrlich’s “magic bullet” concept
of chemotherapy (Kaufmann, 2008), without acknowledging the
network structure of the brain and the properties and behavior of
real world networks as described in the following sections.
COMPLEX REAL WORLD NETWORKS
Reductionism dominated biological research during the last
century and provided a wealth of information regarding the
individual cellular components and their functions. However,
biological functions can rarely be attributed to an individ-
ual molecule. Instead, they are the consequence of complex
interactions between the cell’s numerous constituents, such as
proteins, DNA, RNA, small molecules, and of intercellular inter-
actions (Kitano, 2002; Barabasi and Oltvai, 2004). Therefore, a
key challenge for biology in the twenty-first century is to under-
stand the structure and the dynamics of the complex intra- and
intercellular web of interactions that contribute to the structure
and function of a living cell, organ or organism (Barabasi and
Oltvai, 2004). Thus, reductionism has made its way to holism and
systems biology has emerged as a scientific discipline. It is based
upon the notion that all the properties, function and/or behav-
ior of a given system cannot be determined or explained by the
properties and function of its component parts alone. Instead,
the system as a whole determines in an important way how the
parts behave and as a result new properties emerge (Kitano, 2002).
These “emergent” properties cannot be predicted a priori, based
on the properties of the individual elements. Such is the case
of the mind and of mind states like consciousness, emergent
properties of the brain occurring between multiple physical and
functional levels (Gazzaniga, 2010; Bassett and Gazzaniga, 2011).
An important milestone over the past decade has been the
understanding that the structure and evolution of networks
appearing in social, technological, and natural systems over time
follows a number of basic and reproducible organizing principles,
which can be explained by the application of graph theoreti-
cal analysis to describe network properties (Albert and Barabasi,
2002). A graph is an abstract representation of a network where
nodes or vertices are connected by links or edges (Figure 1). For
more than 40 years scientists treated complex networks as being
FIGURE 1 | Network topologies. (A) An example of a random network with
no high degree hubs, where nodes (red circles) are connected by edges
(black lines). (B) A scale-free network with high degree hubs (gray circles).
(C) A modular network where nodes within a module (i.e., red, green, and
blue modules) are highly connected to each other and only sparsely
connected to nodes of another module.
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random (Erdos and Renyi, 1959). In random graphs, connections
between the network nodes are present with a fixed and equal
likelihood (Erdos and Renyi, 1959). However, Watts and Strogatz
(1998) demonstrated that most real world networks are not
random nor regular lattices, but follow the “small-world” phe-
nomenon, where the path length between nodes (the average of
the shortest distance between pairs of nodes counted in number
of edges) is small, like in random networks, but the clustering
coefficient (the likelihood that neighbors of a node will also be
connected) is high, unlike, random networks. Watts and Strogatz
described the small-world properties of networks found in the
nervous system of the nematode Caenorhabditis elegans, a social
network of actors and the network of power plants in the United
States. A second major discovery in real world network topol-
ogy was presented by Barabasi and Albert (1999). They proposed
a model for the growth of a network where the likelihood that
newly added edges connect to a node depends upon the degree
(number of edges) of this node, following a preferential attach-
ment behavior. Thus, nodes that have a high degree (hubs) are
more likely to get even more edges. This is the network equiva-
lent of “the rich getting richer” (Barabasi and Bonabeau, 2003).
Networks generated in this way maintain the short path length of
small-world networks (Cohen and Havlin, 2003), but are charac-
terized by a degree distribution described by a power law. These
networks are called “scale-free” in the sense that some hubs have
a seemingly unlimited number of links and no node is typi-
cal of the others (Figure 1). Many other small-world networks
have exponential or exponentially truncated power law distri-
butions, implying relatively reduced probabilities of huge hubs
(Amaral et al., 2000; Albert and Barabasi, 2002). Determining the
topology of a network is important in order to understand the
system’s behavior, as power laws emerge when there is a tran-
sition from disorder to order (Barabasi, 2002). The accidental
failure of a number of nodes in a random network can frac-
ture the system into non-communicating islands. In contrast,
scale-free networks are resilient to change, have error toler-
ance and attack vulnerability: they are more robust in the face
of random failures or attacks, but they are highly vulnerable
to a coordinated attack against their Achilles’ heel, the hubs
(Albert et al., 2000). These alternate behaviors acquire utmost
importance when designing pharmacotherapies for network
pathologies.
Since the first description of scale-free networks, most com-
plex networks have been described to have this topology: scientific
papers linked by citations, the World Wide Web (Albert et al.,
1999; Barabasi and Albert, 1999), e-mail networks (Ebel et al.,
2002), epidemic spreads (Pastor-Satorras and Vespignani, 2001),
airline transportation networks (Newman, 2003), metabolic,
protein-protein interaction and gen interaction networks (Jeong
et al., 2000; Podani et al., 2001; Ravasz et al., 2002; Wuchty et al.,
2003; Almaas et al., 2004; Barabasi and Oltvai, 2004; Tong et al.,
2004), to name a few. But what about brain networks?
BRAIN NETWORKS
Only recently graph theoretical analysis has been applied to the
study of brain networks. These has been motivated by the idea
that brain functions are not solely attributable to individual
regions and connections, but are emergent features of the topol-
ogy of the network as a whole, the “connectome” of the brain
(Sporns, 2011a). Moreover, it has been boosted by the advance-
ment of the analysis of brain connectivity both at the struc-
tural and functional levels (Sporns, 2011a). In this section we
will only highlight some important findings and conclusions
derived from the application of graph analysis to the topology
of brain networks. For comprehensive reviews see Reijneveld
et al. (2007), Bullmore and Sporns (2009), Bullmore and Bassett
(2011), Sporns (2011a).
Magnetic resonance imaging (MRI) as well as diffusor ten-
sor/spectrum/kurtosis imaging (DTI/DSI/DKI) and the appli-
cation of graph analysis to some of these data are delivering
increasingly detailed maps of large scale human brain structural
connectivity and of its topology (Figure 2). In addition, graph
analysis to functional connectivity, that is correlated activity
in a network, can be applied to data derived from functional
MRI (fMRI), magnetoencephalography (MEG), and electroen-
cephalography (EEG). One important caveat to the graph-based
study of functional brain organization is how to define the indi-
vidual nodes that makes up a brain network. If the nodes of
the graph do not accurately represent reality then the graph the-
oretic properties will diverge from the true properties of the
system. Therefore, data acquisition and preprocessing are impor-
tant issues (for review see Bullmore and Bassett, 2011). Effective
FIGURE 2 | Graph analysis to brain networks. Structural (including either
gray or white matter measurements using histological or imaging data) or
functional data (including resting-state fMRI, fMRI, EEG, or MEG data) is
the starting point. Nodes are defined (e.g., anatomically defined regions of
histological, MRI or diffusion tensor imaging data in structural networks or
EEG electrodes or MEG sensors in functional networks) and an association
between nodes is established (coherence, connection probability, or
correlations in cortical thickness). The pairwise association between
nodes is then computed, and usually thresholded to create a binary
(adjacency) matrix. A brain network is then constructed from nodes (brain
regions) and edges (pairwise associations that were larger than the chosen
threshold).
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connectivity of brain networks, which refers to information
transfer in a network and has some directionality embedded in
it, can be analyzed by transfer entropy, Granger causality, or
partial directed coherence to generate a directed graph, which
involves estimating the causal influence that each element of a
system exerts on the behavior of other elements (Sporns, 2011b).
However, so far, most graph analyses have been applied to struc-
tural and functional connectivity to generate undirected graphs.
In addition, although most studies use simpler unweighted
graphs, weighted network analysis also has been applied. In these
graphs edges can have continuously variable weights indicating
the strength or effectiveness of connections (Reijneveld et al.,
2007).
Graph analysis of structural and functional connectivity is
consistently showing characteristic non-random properties of
brain networks (Reijneveld et al., 2007; Bullmore and Sporns,
2009; Bullmore and Bassett, 2011; Sporns, 2011c). At the struc-
tural level, several studies have revealed small-world attributes
(Bullmore and Sporns, 2009; Sporns, 2011c). Such is the case of
the analysis of human brain networks on the basis of correlations
in cortical gray matter thickness measured using MRI (He et al.,
2007; Chen et al., 2008), DTI, and tractography of cortical and
basal brain gray matter areas (Iturria-Medina et al., 2007, 2008;
Gong et al., 2009) and diffusion spectrum imaging of cortical
regions (Hagmann et al., 2007). In addition, these studies demon-
strate the presence of hierarchical brain modules. Modularity
refers to the existence of clusters or “network communities”
whose constituent brain regions are more densely connected to
each other than to regions in other modules (Figure 1). Thus,
neurons and brain regions that are spatially close have a relatively
high probability of being connected forming a module, whereas
connections between spatially remote neurons or brain regions
are less likely. Since longer axonal projections are more expensive
in terms of their material and energy costs, this layout mini-
mizes wiring costs (Chklovskii et al., 2002). Nodes of high degree,
hubs, exist within modules, and also connect to hubs in other
modules, thus maintaining the short path length typical of small-
world networks, providing high global efficiency of parallel infor-
mation transfer (Bullmore and Sporns, 2009; Sporns, 2011c).
However, structural brain networks seem to lack extremely
high degree nodes characteristic of a scale-free network and
rather follow an exponentially truncated power law distribution
(He et al., 2007).
Additional information of brain network topology has derived
from functional imaging and electrophysiology. Graph analysis
from fMRI data has described small-world topology of brain net-
works, with a truncated power law distribution (Salvador et al.,
2005; Achard et al., 2006). In contrast, scale-free topology has
been also described in networks derived from fMRI recordings
both during task and resting state (Eguiluz et al., 2005; van den
Heuvel et al., 2008). Functional connectivity also has been ana-
lyzed using a measure of generalized synchronization and then
thresholded to generate functional networks, in several studies
derived from MEG data sets (Stam and van Dijk, 2002; Stam,
2004). In addition, graph analysis has been applied to wavelet
correlation estimates of frequency-dependent functional connec-
tivity between MEG sensors (Bassett et al., 2006). These studies
have shown small-world properties of brain networks. Graph
analysis to EEG wavelet coefficients found small-world properties
in the alpha and beta band networks (Jin et al., 2011). The devel-
opment of time-varying graphs with fixed nodes but evolving
links derived from scalp EEG recordings reported both small-
world and scale-free topology of brain networks (Dimitriadis
et al., 2010). Two further studies that have used alternate analysis
different from graph theory to EEG recordings, have also shown
scale-free properties of brain activity: the analysis of fine temporal
structures of arrhythmic brain activity by using nested-frequency
EEG analysis (He et al., 2010) and EEG microstates (van de Ville
et al., 2010).
From the available structural and functional studies it can be
concluded that large-brain networks exhibit a similar organiza-
tion, with several studies demonstrating functional clusters or
modules, highly connected hub nodes, short path lengths, and
high global efficiency. The general picture that arises so far from
structural studies is that brain networks have small-world topolo-
gies but are not scale-free. However, at the functional level it is
still a matter of debate whether they are also scale-free (Reijneveld
et al., 2007). Differences might derive from the fact that different
methods describe different aspects of neuronal networks. From
an evolutionary perspective, it can be argued that small-world
brain networks have been selected to solve the economic problem
of maximizing information processing efficiency, while minimiz-
ing wiring costs (Bullmore and Sporns, 2009). Structural studies
have revealed important hubs within the parietal and frontal lobes
of the cerebral cortex (Iturria-Medina et al., 2008; Gong et al.,
2009; van den Heuvel and Sporns, 2011). Most importantly, sev-
eral independent diffusion imaging data sets have reported a high
centrality for the precuneus, the posterior cingulate cortex, and
neighboring regions (Hagmann et al., 2007, 2008; Iturria-Medina
et al., 2007, 2008). A very recent study that applied graph analy-
sis to DTI data showed the presence of 12 strongly interconnected
bihemispheric hub regions, comprising the precuneus, superior
frontal, and superior parietal cortex, as well as the subcortical hip-
pocampus, putamen, and thalamus (van den Heuvel and Sporns,
2011). Importantly, these hub regions were not only individually
central but formed a “rich club” organization, since they were
found to be more densely interconnected than would be expected
based only on their degree. This rich club organization of the
human brain connectomemight optimize global brain communi-
cation efficiency for healthy cognitive brain functioning (van den
Heuvel and Sporns, 2011).
The analysis of underlying structural and functional network
topologies provides a powerful tool to understand the system’s
behavior that cannot be attained with other approaches to com-
plex systems. Thus, if the brain had a scale-free topology, it would
be very vulnerable to hub failures or attacks (Albert et al., 2000).
In their analysis of discrete wavelet transform to fMRI time series,
Achard and collaborators (2006) described small-world proper-
ties of cortical and subcortical regions with a truncated power law
distribution, which were as resilient to random error, but more
resistant to targeted attacks than scale-free networks. Moreover,
up to 40% of the most connected nodes in the brain network
could be eliminated before precipitating a 50% reduction in size
(and twofold increase in path length) of the largest connected
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cluster. Therefore, the small-world architecture of the brain may
confer distinctive benefits in terms of robustness to both random
elimination of nodes and selective attack on hubs (Achard et al.,
2006). Thus, it increases resilience and reduces vulnerability to
individual hub attacks. In addition, the rich club organization
described by van denHeuvel and Sporns (2011) provides an addi-
tional level of resilience to its core, in case of malfunction of any
one of its individual key hubs.
BRAIN NETWORKS IN PATHOLOGY
Only very recently graph theoretical analysis has been applied
to a wide variety of CNS disorders and, therefore, the power
of this approach toward understanding brain pathology is at its
infancy. Changes in network topology have been analyzed in
disorders such as schizophrenia, epilepsy, Alzheimer’s disease,
multiple sclerosis, acute depression, fronto-temporal lobe degen-
eration, stroke, spinal cord injury, early blindness, and attention
deficit hyperactivity disorder (for reviews see Reijneveld et al.,
2007; Bassett and Bullmore, 2009; Bullmore and Sporns, 2009).
Reduction in small-world properties has been described in
patients with Alzheimer’s disease, associated with less efficient
information exchange between brain areas, supporting the dis-
connection hypothesis proposed for this pathology, as well as
for many other neurological and psychiatric disorders (Catani
and Ffytche, 2005). A loss of small-world properties has also
been described in schizophrenia, again supporting the discon-
nection hypothesis. Network organization derived from graph
analysis appears to have increased randomization (Bassett et al.,
2008; Lynall et al., 2010; Rubinov and Bassett, 2011) and to
be less cost-efficient (Bassett et al., 2009) when compared with
healthy controls. In addition, topological abnormalities in peo-
ple with schizophrenia include a reduced hierarchy of the mul-
timodal cortex (Bassett et al., 2008) and less globally inte-
grated brain structures, with a reduced central role for key
frontal hubs, resulting in a limited structural capacity to inte-
grate information across brain regions (Lynall et al., 2010;
van den Heuvel et al., 2010). Loss of small-world organiza-
tion has also been reported in depressed patients during sleep
(Leistedt et al., 2009), increased randomization in frontal lobe
epilepsy (van Dellen et al., 2009) and shift to more regular net-
works in children with attention deficit hyperactivity disorder
(Wang et al., 2009).
Thus, it seems that in general, brain pathology leads to alter-
ation in small-world network properties with a decreased global
integration. Although, it is too soon to fully appreciate the power
of graph analysis in CNS disorders, it undoubtedly opens new
avenues toward understanding brain diseases. Changes in net-
work topology might be used as clinically useful diagnostic mark-
ers and to monitor progression of disease states (Bullmore and
Sporns, 2009). Moreover, graph theory allows identifying hubs
and modeling network attacks (Albert et al., 2000), which might
give hints to determine which treatment approach is the best
option at the network level.
NETWORK PHARMACOLOGY
One major outcome derived from the fact that most com-
plex biological systems are networks, either small-world and/or
scale-free, very robust, and resilient to change, has been a very
recent shift in the philosophy behind drug design and phar-
macotherapy, which is leading to a new trend: in Andrew
Hopkins’ own words “network pharmacology: the next paradigm
in drug discovery” (Hopkins, 2008). This means moving away
from Ehrlich’s “magic bullets” that target individual chemorecep-
tors or “disease-causing genes” (Kaufmann, 2008), into “magic
shotguns”, “promiscuous” or “dirty drugs” that target “disease-
causing networks” (Roth et al., 2004; Csermely et al., 2005;
Sams-Dodd, 2005; Hopkins, 2008). Following systems biology
principle of emergence, combinations of compounds could be
more effective than the sum of the effectiveness of the indi-
vidual agents themselves (Keith et al., 2005; Kung et al., 2005).
Shotguns canmake a dramatic impact on disease outcome, as evi-
denced by the success of the multidrug antiretroviral therapy in
decreasing human immunodeficiency virus mortality rates (Imaz
et al., 2011). Moreover, multiple attacks have been selected in
nature as defense systems and communication, therefore, magic
shotguns seem as an evolutionary selected feature. Thus, snake
(Bohlen et al., 2011), spider (Rash and Hodgson, 2002; Siemens
et al., 2006) cone snail (Olivera and Teichert, 2007) and scorpion
(Rodriguez de la Vega et al., 2010) venoms comprise multi-
molecules, plants employ batteries of various factors to avoid
pathogenic attacks (Uma et al., 2011) and honey bee queens
produce a mandibular pheromone that is a cocktail of nine inter-
acting components required to attract worker bees, to attract
drones for mating and to prevent workers from reproducing
(Keeling et al., 2003).
The importance of multi-targeting pharmacology has also
recently been encouraged by the observation that novel well-
tolerated protein kinase drugs, such as Gleevec (Imatinib) and
Sutent (SU11248), exhibit binding promiscuity for multiple
kinases and therefore are less selective than initially thought
(Hampton, 2004; Fabian et al., 2005). Polypharmacology is prob-
ably not a novel notion, however, what is new is the acknowl-
edgment of its benefits for efficacy. Thus, the pleiotropic actions
of clozapine are probably responsible for its exceptionally ben-
eficial actions in schizophrenia and related disorders. Clozapine
has a very complex pharmacological profile, with high affinity
for a number of receptors, including dopamine (D4), serotonin
(5-HT2A, 5-HT2C, 5-HT6, 5-HT7), muscarinic (M1, M2, M3,
M4, M5), adrenergic (α1- and α2-subtypes), and other biogenic
amine receptors (Roth et al., 2004). Moreover, many newer gen-
eration anti-psychotics might have failed in the clinics because
of higher target specificity (Roth et al., 2004). Likewise, the
pleiotropic actions of antidepressants on signal transduction
and neuronal mitogenesis are probably required for the bene-
ficial effects of antidepressants on mood disorders. Moreover,
the “dual- and triple-action” antidepressants, which inhibit the
reuptake of both 5-HT and other biogenic amines (for exam-
ple, dopamine and noradrenaline), have been shown to be more
effective than “single-action” antidepressants (Roth et al., 2004;
Millan, 2006). In a recent study, Yildirim et al. (Yildirim et al.,
2007) applied network analysis to 1178 FDA-approved drugs
and drugs targets as of March 29, 2006, in order to understand
drug design strategies followed by the pharmaceutical indus-
try. To investigate the relationships between approved drugs and
Frontiers in Systems Neuroscience www.frontiersin.org January 2012 | Volume 6 | Article 1 | 5
Elgoyhen et al. Tinnitus network pharmacology
their targets they built a bipartite drug-target network by inte-
grating publicly available drug data with genetic-disease associa-
tions, gene-expression information and protein-protein interac-
tion data. If drugs acted selectively on single targets, one would
expect isolated, bipartite nodes and not a network structure. Not
surprisingly, the authors found a rich network of polypharmacol-
ogy interactions between drugs and their targets. Moreover, drugs
acting on single targets were the exception. They found a giant
component, the largest connected component of the network,
with 476 drugs comprising a tightly interconnected neurological
drug cluster. Thus, although initially designed as magic bullets,
most CNS-acting drugs are magic shotguns and this is prob-
ably the reason behind the fact that they are effective in CNS
disorders.
The use of multi-targets is further supported by the work
of Agoston and collaborators (Agoston et al., 2005). Most stud-
ies that have analyzed the stability of networks under failures
or attacks have used a model with a complete elimination of
an element from the network in order to assess network stabil-
ity (Albert et al., 2000; Watts, 2002; Shargel et al., 2003; Valente
et al., 2004). Agoston and collaborators (Agoston et al., 2005),
however, used an alternative approach, where they studied if
the partial inactivation of several targets is more efficient than
the complete inactivation of a single target. This scenario most
closely resembles pharmacotherapy, since at plasma concentra-
tions attained with pharmacological doses, most drugs probably
weaken targets rather completely ablate them. Moreover, if only
a partial weakening of targets is needed, this could probably be
attained at lower plasma concentrations, thus requiring lower
doses with concomitant fewer side effects. Partial attacks also
mimic other physiological scenarios and treatments, where the
complete elimination of a node within a network is a rather
unusual phenomenon. By analyzing the regulatory scale-free net-
work of E. coli and S. cerevisiae Agoston and collaborators (2005)
concluded that the efficacy of attenuation of targets by multi-
target attacks is higher than that of a single-target knockout. In
terms of pharmacology, this suggests that drugs with multiple tar-
gets or drug combinations might have a better chance to affect the
complex equilibrium of the whole system than single target drugs.
Moreover, it is sufficient that these multi-target drugs affect their
targets only partially, which correlates with the low-affinity inter-
actions of most drugs with several of their targets (Csermely et al.,
2005).
Given that promiscuous or dirty drugs are probably more effi-
cient than highly selective ones, can they be designed rationally?
In principle, the magic shotgun approach can be attained in four
ways: using a drug withmultiple mechanisms of actions, prescrib-
ing a combination of drugs, the development of multicomponent
drugs that contain two or more active ingredients formulated in
the same delivery device, or a designer polypharmacology, e.g.,
a drug with two or more pharmacophores (Borisy et al., 2003;
Morphy et al., 2004; Roth et al., 2004; Csermely et al., 2005;
Keith et al., 2005; Hopkins, 2007, 2008). The complexity imposed
by exploring dosage ranging, drug interaction, and safety stud-
ies may significantly raise the practical cost and complexity of
developing combination therapies. Potential drug interactions
at the pharmacokinetic and pharmacodynamic level have to be
considered, since two drugs that themselves are efficient and
safe when prescribed separately might not necessarily be effi-
cient and safe when used in combination (Hopkins et al., 2006).
However, these problems can be reduced with polypharmacology,
since it allows combination therapies at lower doses, result-
ing in higher efficacy and/or reduced side-effects compared to
monotherapies (Morphy et al., 2004; Keith et al., 2005). For exam-
ple, low-dose combinations of calcium-channel blockers and
angiotensin-receptor antagonists are effective for the treatment
of hypertension (Andreadis et al., 2005) and low doses of atypi-
cal antipsychotics, such as quetiapine, olanzapine, or risperidone,
can improve the antidepressant efficacy of selective serotonin
reuptake inhibitors, such as fluoxetine, in the treatment of refrac-
tory depressed patients (Rasmussen, 2006). Pharmacodynamic
and pharmacokinetic relationship, are substantially less complex
if polypharmacological action is derived from a single agent and
thus approaches to developmultifunctional drugs withmore than
one pharmacophore are under way (Morphy et al., 2004). An
example is ladostigil (TV3326), a novel neuroprotective agent
being investigated for the treatment of neurodegenerative disor-
ders like Alzheimer’s disease, Lewy body disease, and Parkinson’s
disease. It combines the acetylcholinesterase and monoamino
oxidase (MAO)-A and -B activities in one molecule and was
developed by combining the active (MAO inhibitory and neu-
roprotective) pharmacophore of the antiparkinsonian MAO-B
inhibitor rasagiline with the carbamate cholinesterase inhibitory
moiety of the anti-Alzheimer’s drug rivastigmine (Weinstock
et al., 2006).
Finding the right combination of targets to aim imposes a fur-
ther complexity when compared to single target therapies. This
is the main challenge faced at present in network pharmacology
and the field is still “lost in translation” in trying to understand
the meaning and the outreach of this new discipline. Following
network biology principles, drug discovery approaches might
involve the identification of combinations of small molecules
that perturb networks in a desired fashion. Drug combinations
have been used with compounds already known to be effective
in the disease of interest, or where there is a clear rationale for
the combination (Millan, 2006). However, such limited combi-
nation testing samples only a tiny fraction of the combinatorial
pharmacological space and is unlikely to result in the selection
of optimal combinations among the very large number of pos-
sibilities. A small number of compounds will provide a very
large number of combinations and, therefore, efficient screening
methods are needed. High-throughput based behavioral screen-
ings which rely on the semi-automated screening of candidate
drugs in broad-based behavioral assays in animals, might be
used to screen libraries of compounds and find those combi-
nations which are enriched for activity at CNS targets. These
approaches that are increasingly offered by specialized compa-
nies, have the advantage that they analyze responses to drugs at
the level of entire organisms and, therefore, based in their bio-
logical function, without the need of having a lead compound,
as needed in in vitro assays (Roth et al., 2004; Millan, 2006).
In addition, large scale multielectrode brain recordings in ani-
mals now offer unique opportunities to assay spatiotemporal
patterns of neuronal assemblies in brain networks (Buzsaki, 2004;
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Lehew and Nicolelis, 2008). Graph analysis applied to these mul-
tielectrode array approaches might aid toward defining changes
in brain topology and hubs in animal models of disease and
restoration of the topology during treatment. These methods
can provide insights into network-level mechanisms of action of
compounds, even when synapse or receptor-level mechanisms
are not understood. In addition, it is likely that graph anal-
ysis to structural and functional brain networks will further
broaden our understanding of treatment effects, will aid toward
the design of new therapeutical approaches and help to decipher
how therapeutically effective pharmacotherapeutic treatments act
on topologically sub-optimal network configurations in patients
(Bullmore and Sporns, 2009). Thus, the potential use of fMRI on
optimizing drug development (phMRI, pharmacological MRI)
is beginning to be appreciated and promises to be part of a
sequence of events that could transform drug development for
disorders of the CNS (Honey and Bullmore, 2004; Borsook et al.,
2006).
Although the rationale behind the use of magic shotguns,
promiscuous or dirty drugs is compelling, pharmaceutical indus-
tries are being very slow in conquering these approaches. This
is probably due to the fact that it is still a challenge to decipher
which combinatorial assembly of targets (nodes) to aim, on the
one hand, and which combination of dirty drugs is needed in
order to best weaken those nodes, on the other. Moreover, the
balancing act of optimizing multiple activities, while minimizing
unwanted off-target side effects, is a challenge (Hopkins, 2007,
2008). However, network pharmacology will probably become
an essential component of drug-development strategies. Indeed,
network concepts have already been applied in drug discovery
studies in anti-cancer drugs for example (Azmi et al., 2010).
Moreover, drug-target networks linking approved or experimen-
tal drugs to their protein targets have helped to organize and
visualize the considerable knowledge that exists concerning the
interplay between diseases, drug targets and drugs (Yildirim et al.,
2007; Keiser et al., 2009). The analysis of these networks have
indicated that many drugs can be considered palliative, since they
do not target the actual disease-associated proteins but proteins
in their network neighborhood (Yildirim et al., 2007) and have
aided to predict new molecular targets for known drugs (Keiser
et al., 2009). Interestingly, Loging and collaborators (Loging
et al., 2007) have suggested a high-throughput electronic-biology
approach based on in silico data mining of existing databases
and integration of this information for drug discovery. These few
examples show the power of network approaches. Examples of
how these approaches might be applied to tinnitus are developed
in the following section.
BACK TO TINNITUS
An increasing amount of work is supporting the proposal that
tinnitus is a CNS pathology where dynamic, multiple, paral-
lel, and overlapping brain networks are at stake (Jastreboff,
1990; Eggermont and Roberts, 2004; Weisz et al., 2007; Schlee
et al., 2009a,b; De Ridder et al., 2011a; Leaver et al., 2011).
Thus, results obtained in research animals (Eggermont and
Roberts, 2004) and humans (Muhlnickel et al., 1998) have
shown cortical map plasticity and reorganization of the primary
auditory cortex, which correlates with the intensity of the per-
ceived sound (Muhlnickel et al., 1998). Moreover, increased
spontaneous activity and increased neural synchrony in corti-
cal neurons have been reported in several regions of the CNS
(Norena and Eggermont, 2003; Eggermont, 2007). In addition,
MEG studies have shown that tinnitus is related to gamma band
activity in the auditory cortex, along with decreased alpha and
increased theta or delta activity (Llinas et al., 1999; Weisz et al.,
2005, 2007) and EEG studies have further shown that gamma
band activity in the auditory cortex reflects the tinnitus intensity
(van der Loo et al., 2009). These map changes and cortical syn-
chronized activity are necessary but probably not sufficient for the
conscious perception of the phantom sound, which needs func-
tional connectivity to a network of higher order brain “neuronal
global workspace” areas (De Ridder et al., 2011a). In accordance,
an MEG study has shown a global tinnitus network of long-
range cortical connections outside the central auditory system
including the right parietal cortex, the right frontal lobe and the
anterior cingulate cortex, which project top-down influences on
the primary auditory cortex and thus amplify neuronal activ-
ity in the sensory cortex (Schlee et al., 2008, 2009a). Moreover,
tinnitus has an affective component, since in some patients it
is accompanied by stress, depression, and anxiety. Therefore, in
addition to the perceptual network, a distress network is acti-
vated which comprises the medial temporal lobe (amygdala and
hippocampus), parahippocampal areas, insula, and the anterior
cingulate cortex (Vanneste et al., 2010; De Ridder et al., 2011b).
Salience and mnemonic networks are also activated, evidenced by
enhanced activity of the amygdala in positron emission tomogra-
phy imaging (Mirz et al., 2000), by changes in the hippocampal
area and by transient tinnitus diminution after suppression of
the amygdalo-hippocampal complex by amytal (De Ridder et al.,
2006, 2011b). Thus, there is compelling evidence for a distributed
tinnitus brain network, which includes sensory auditory areas
together with cortical regions involved in perceptual, emotional,
mnemonic, attentional, and salience functions (De Ridder et al.,
2011a).
In spite of the above existent electrophysiological and func-
tional imaging data derived from tinnitus patients, there is no
published work describing the application of graph theoretical
analysis to this data. Graph analysis to the tinnitus network might
complement insight derived from the study of more localized
small brain areas. Moreover, it might be worth applying graph
analysis to structural networks, since structural deficits in tinni-
tus patients have been described in limbic and auditory pathways
by structural imaging approaches (Lee et al., 2007; Landgrebe
et al., 2009; Crippa et al., 2010; Husain et al., 2011; Leaver et al.,
2011). A clear analogy exists between phantom pain and tinni-
tus and the available knowledge concerning phantom pain and
neuropathic pain has advanced our understanding of the under-
lying pathophysiological changes in tinnitus (Moller, 2007; De
Ridder et al., 2011a). However, there is no published data show-
ing the application of graph analysis to these pathologies either,
therefore, the topology of brain networks in phantom perception
remains unknown. Graph theory could help to refine the topol-
ogy of the tinnitus network, with the identification of nodes and
high degree hubs, modules and clusters. Moreover, simulation of
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network attacks might aid toward the design of better treatment
strategies.
The global tinnitus network of long-range cortical connec-
tions outside the central auditory pathway described by Schlee
and collaborators (2008, 2009a) by MEG and phase synchro-
nization in the gamma frequencies, speaks toward functionally
integrated distributed brain regions. Synchronization of oscil-
latory responses in the beta- and gamma-band is involved
in a variety of cognitive functions, such as routing of sig-
nals across distributed cortical networks, perceptual grouping,
attention-dependent stimulus selection, sensory-motor integra-
tion, working memory and perceptual awareness (Uhlhaas and
Singer, 2006). Thus, synchronization plays a crucial role in the
exchange of information between cortical areas and both phase
and strength of neuronal oscillations in the gamma frequency
band influence the amount and speed of information transfer
(Buehlmann and Deco, 2010). The global tinnitus network of
long-range cortical connections resembles the global neuronal
workspace model, where neurons distributed in distant corti-
cal areas need to be accessed for conscious perception (Dehaene
and Naccache, 2001; Baars, 2002, 2005). Interestingly, the topol-
ogy of the global neuronal workspace has been just recently
analyzed by graph theoretical analysis during a cognitive effort-
ful task (Kitzbichler et al., 2011). Emergence of a less clustered
and less modular network configuration, more globally efficient,
with more long-distance synchronization between brain regions,
especially in functional networks oscillating at beta and gamma
frequency intervals, was reported. This indicates that entrance
to the global neuronal workspace breaks modularity in order
to allow human brain functional networks to transiently adopt
a more efficient but less economical configuration (Kitzbichler
et al., 2011). Moreover, the authors propose that, as cognitive
effort increases, emergent long-range synchronization provides
topological short-cuts between cortical areas that are otherwise
segregated from each other in the more modular configura-
tion of the network under cognitively non-demanding conditions
and, therefore, increases the global efficiency of the network
to subserve transfer of parallel information. This finding is in
accordance with the dynamic model of global workspace forma-
tion, in which modular subsystems with a locally synchronized
community structure during unconscious processing are sud-
denly replaced by the ignition of a globally synchronized network
of neurons with long-range axons densely distributed in pre-
frontal, parieto-temporal, and cingulate cortices, in response to
a consciously attended stimulus (Dehaene and Changeux, 2005,
2011). Thus, following the graph analysis of the neuronal global
workspace one could predict a non-random tinnitus network
with more long-distance synchronization between brain regions
and shorter path lengths which increase global efficiency of infor-
mation transfer. Interestingly, several independent graph analysis
to structural studies in normal subjects have reported a high
centrality for the precuneus, the posterior cingulate cortex and
neighboring regions (Hagmann et al., 2007, 2008; Iturria-Medina
et al., 2007, 2008), two regions that have been shown to be part of
the tinnitus network (Schlee et al., 2009b; Vanneste et al., 2010; De
Ridder et al., 2011b). Since the precuneus and the posterior cingu-
late cortex are both pivotal for conscious information processing
(Dehaene and Changeux, 2011), it might be the case that they
acquire a higher degree in the phantom percept network.
Being a complex network pathology, tinnitus treatment would
best benefit from a promiscuous or multi-target drug approach.
This is supported by a recent report in which deanxit, the com-
bination of the antidepressant melitracen and the antipsychotic
flupentixol, has proven superior to placebo in a cross-over trial as
add-on medication to clonazepam (Meeus et al., 2011). Although
there is no tinnitus approved drug on the market, one serendip-
itous discovery in tinnitus pharmacotherapy deserves further
analysis. Beginning with the accidental discovery of the tinni-
tus suppressing effect of the local anesthetic procaine (Bárány,
1935), intravenous administration of local anesthetics such as
lidocaine have been used in the treatment of tinnitus (for review
see Trellakis et al., 2007). Available data indicate that lidocaine is
able to reduce tinnitus in 60% of patients in a dose-dependent
manner (Haginomori et al., 1995; Otsuka et al., 2003; Baguley
et al., 2005). Because of poor biological availability after oral
administration, lidocaine is not effective when taken orally. Thus,
other anti-arrythmics or local anesthetics have been used without
much success. This includes tocainide, flecainide, and mexiletine
(Blayney et al., 1985; Hulshof and Vermeij, 1985b; Fortnum and
Coles, 1991; Dobie, 1999; Trellakis et al., 2007). Moreover, based
on the fact that lidocaine blocks voltage-gated sodium chan-
nels, some anticonvulsants that also act on voltage-gated sodium
channels like carbamazepine have been used in tinnitus, without
much success (Donaldson, 1981; Marks et al., 1981; Hulshof and
Vermeij, 1985a). This accidental discovery might be further eval-
uated and acted upon under the light of network analysis. Two
examples of network approaches to this observation are described
below.
Brain imaging studies have shown changes in activity in sev-
eral CNS regions after lidocaine infusion (Mirz et al., 1999;
Andersson et al., 2000; Reyes et al., 2002). Graph analysis of
functional brain networks might help refine the hubs that are
mostly influenced by lidocaine in tinnitus-sensitive patients. This
might help understand the mechanism of action of this com-
pound and guide further developments. This type of analysis has
been applied to the effect of the dopamine receptor subtype 2
antagonist sulpiride, showing that it impairs network efficiency
by an effect most clearly localized to dorsal cingulate and lateral
temporal cortical hubs (Achard and Bullmore, 2007). Moreoever,
these findings have been correlated with changes in the topology
of the aging brain (Achard and Bullmore, 2007).
Lidocaine has pleiotropic effects on several proteins aside from
the well-known block of voltage-gated sodium channels (Trellakis
et al., 2007). Following an e-biology approach (Loging et al.,
2007), one could mine existing databases (including, but not
restricted to, medline) to define the pharmacological space of
lidocaine targets. Moreover, one could follow the same approach
to define the pharmacological space of other local anesthetics,
antiarrythmics, and anticonvulsants. A drug-target network link-
ing drugs to their protein targets (Yildirim et al., 2007; Keiser
et al., 2009) would help organize and visualize these data, define
the target interplay for the different compounds and finally make
predictions concerning the add-on effects that lidocaine has when
compared to compounds that are non-effective in tinnitus.
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These two examples are just a glimpse of how network anal-
ysis might lead us forward in our understanding of tinnitus and
of its treatment. Most importantly, it will move us further away
from a reductionist way of looking at tinnitus. Tinnitus cannot
be seen solely as a pathology of increased excitation or decreased
inhibition at different relays of the auditory pathway including
the cochlea, cochlear nucleus, inferior colliculus, and sensory
auditory cortex. Moreover, the notion of emergence of complex
systems might guide us further in tinnitus research and pharma-
cotherapy. Thus, for example, although benzodiazepines are used
in tinnitus patients with the aim of increasing inhibitory gabaer-
gic pathways, recent studies have shown that GABAA receptors
can be excitatory in the mature cortex depending on the excitabil-
ity of the network the neuron is embedded in and on the spa-
tiotemporal relationship to other depolarizing stimulus (Gulledge
and Stuart, 2003; Szabadics et al., 2006 and references thereof).
These findings imply that different brain regions might qualitative
and/or quantitative respond differently to drugs. At least in part,
this might be due to drug actions on emergent network properties
conferred to neurons as the result of their membership in the net-
work, rather than being solely due to the intrinsic binding of the
drug to a specific receptor in the neuron.
CONCLUSIONS
In summary, graph analysis to complex networks is aiding toward
understanding the behavior of the brain in health and disease.
Being tinnitus a CNS disorder wheremultiple parallel overlapping
networks are disturbed, graph analysis might aid to identify the
topology of the network including its hubs. Since brain networks
are best treated with multi-target drugs that attack the disease-
causing network, tinnitus pharmacological treatments could ben-
efit from dirty or promiscuous drugs. Network analysis to tinnitus
pathology and treatment might help to look for the right thing, in
the right place and at the right time.
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